Satisfaction with care among patients with non-metastatic breast cancer: development and first steps of validation of the REPERES-60 questionnaire

Défossez, Gautier; Mathoulin‐Pélissier, Simone; Ingrand, Isabelle; Gasquet, Isabelle; Sifer-Rivière, Lynda; Ingrand, Pierre; Salamon, Roger; Migeot, Virginie

doi:10.1186/1471-2407-7-129

Cited by 45 publications

(88 citation statements)

References 39 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While protein bound paclitaxel can be administered more quickly and is considered water-soluble [15,53], the underlying problems with side effects and damage to normal, healthy cells and tissues still remains. As such, treatment effectiveness is still based not only on cancer stage at diagnosis, but also patient responsiveness and the overall health of the patient [41,[54][55][56].…”

Section: Discussionmentioning

confidence: 99%

The Natural Product NI-07, Is Effective Against Breast Cancer Cells While Showing No Cytotoxicity to Normal Cells

Gollahon¹

2011

TOBCANJ

View full text Add to dashboard Cite

Abstract:With the exception of a few anticancer agents, most breast cancer chemotherapeutics currently used have devastating effects on normal cells. We investigated the effectiveness of the natural product NI-07, derived from Arctium lappa, to determine its killing potential on breast cancer cells and its cytotoxic effects in breast normal cells. The breast cancer cell lines HCC1419, MCF7, MDA-MB-231, MDA-MB-468, SKBR3, the normal mammary epithelial cell line HME 50 HT and the normal mammary fibroblast cell line CCD-1074sk were analyzed in concurrently treated cultures of NI-07, Taxol™ or Untreated. NI-07-treated and Taxol™ -treated cells were cultured for two weeks to assess cell resistance/recovery. Cell viability was determined by cell counts, Trypan Blue exclusion and microscopy. Additionally, cell viability and cytotoxicity were measured by XTT. Statistical significance (p 0.05) of NI-07 to Untreated or Taxol™ was first determined using Two-Way ANOVA. Identified significant differences were further analyzed by One-Way ANOVA and Tukey's test for honestly significant differences. The effect size of NI-07 compared to untreated or Taxol™ was determined using Cohen's d. Our results showed significant declines in cell viability occurring in NI-07-treated cancer cells after 48 hours of treatment in contrast to the more rapid effect of Taxol™ (<24h). Additionally, cancer cell recovery was less effective in NI-07 versus Taxol™. Furthermore, NI-07 showed no cytotoxicity in normal cells. This lack of cytotoxicity, coupled with its killing efficiency in cancer cells, suggests that NI-07 could potentially make a strong anti-cancer compound or neo-adjuvant to current chemotherapy-based treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

The Natural Product NI-07, Is Effective Against Breast Cancer Cells While Showing No Cytotoxicity to Normal Cells

Gollahon¹

2011

TOBCANJ

View full text Add to dashboard Cite

show abstract

“…15 The assessment of the patients' satisfaction also provides indications for improvement of care in a particular hospital. 16 Several studies have been done to study patient satisfaction in cancers like gastroesophageal, 17 breast, 18,19 colorectal, 20 lung, 21 prostate, 21 and gynecological. 6,22 These studies are described in Tables 1 and 2.…”

Section: Studies Investigating Patient Satisfaction With Cancer Care mentioning

confidence: 99%

Distribution and determinants of patient satisfaction in oncology: A review of the literature

Lis

Rodeghier²,

Gupta³

2009

PPA

View full text Add to dashboard Cite

Abstract:Cancer is one of the leading causes of morbidity and mortality in the United States. It places considerable mental, physical, and emotional stress on patients and requires them to make major adjustments in many key areas of their lives. As a consequence, the demands on health care providers to satisfy the complex care needs of cancer patients increase manifold. Of late, patient satisfaction has been recognized as one of the key indicators of health care quality and is now being used by health care institutions for monitoring health care improvement programs, gaining accreditation, and marketing strategies. The patient satisfaction information is also being used to compare and benchmark hospitals, identify best-performance institutions, and discover areas in need of improvement. However, the existing literature on patient satisfaction with the quality of cancer care they receive is inconsistent and heterogeneous because of differences in study designs, questionnaires, study populations, and sample sizes. The aim of this review was therefore to systematically evaluate the available information on the distribution and determinants of patient satisfaction in oncology.

show abstract

“…These studies are useful for professionals because, among other reasons, they estimate the expected values for each country and for different groups of patients and explore whether the questionnaires have a good psychometric functioning. Few patient satisfaction questionnaires have been developed specifically for cancer patients [12][13][14][15][16][17][18][19] and none has been created in a cross-cultural context.…”

Section: Introductionmentioning

confidence: 99%

The EORTC cancer in-patient satisfaction with care questionnaire: EORTC IN-PATSAT32

Arrarás

Vera²,

Martínez³

et al. 2009

Clin Transl Oncol

View full text Add to dashboard Cite

show abstract

Satisfaction with care among patients with non-metastatic breast cancer: development and first steps of validation of the REPERES-60 questionnaire

Cited by 45 publications

References 39 publications

The Natural Product NI-07, Is Effective Against Breast Cancer Cells While Showing No Cytotoxicity to Normal Cells

The Natural Product NI-07, Is Effective Against Breast Cancer Cells While Showing No Cytotoxicity to Normal Cells

Distribution and determinants of patient satisfaction in oncology: A review of the literature

The EORTC cancer in-patient satisfaction with care questionnaire: EORTC IN-PATSAT32

Contact Info

Product

Resources

About